# A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19

> **NCT04401475** · PHASE2,PHASE3 · SUSPENDED · sponsor: **Edesa Biotech Inc.** · enrollment: 644 (estimated)

## Conditions studied

- COVID-19
- ARDS

## Interventions

- **BIOLOGICAL:** SOC plus 15mg/kg EB05 IV
- **OTHER:** SOC plus Placebo IV

## Key facts

- **NCT ID:** NCT04401475
- **Lead sponsor:** Edesa Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-11-25
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 644 (ESTIMATED)
- **Why stopped:** Edesa has made the decision to suspend this study solely for business reasons. The study stop is not related to any safety concerns of the product.
- **Last updated:** 2024-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04401475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04401475, "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04401475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*